Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
Nektar Therapeutics announced three oral presentations of Phase 2b rezpegaldesleukin data at the EADV Congress 2026 in Vienna, September 30 to October 3. The highlight is new 6-month (24-week) off-treatment data from the 92-patient REZOLVE-AA study evaluating durability of response in severe-to-very-severe alopecia areata, completed in September 2026. The company will host an investor call on October 1, 2026 at 8:00 AM ET to discuss the new data, joined by Mount Sinai's Dr. Benjamin Ungar.
Key figures
- Drug Name
- rezpegaldesleukin (REZPEG, NKTR-358)
- Phase Of Trial
- Phase 2b
- Rezolve aa patients
- 92
- Rezolve ad patients
- 393
- Off treatment followup weeks
- 24
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.